Oncode Scientific Sdn Bhd
201501029484 (1154805-X)
Leading the Precision Medicine Revolution in Asia
Since 2015, Oncode Scientific Sdn Bhd has emerged as a trailblazer in the realm of precision medicine, setting new benchmarks in cancer molecular diagnostics. Our multidisciplinary team, comprising top-tier experts from molecular science and clinical practice, brings together decades of experience in medical diagnostics and research. At our cutting-edge facilities in Malaysia, we spearhead one of Asia’s most pioneering precision medicine initiatives, specializing in both solid tumors and hematologic cancers. Our relentless pursuit of innovation drives us to constantly challenge the status quo, exceeding clinical and diagnostic standards to deliver groundbreaking medical solutions. Oncode is dedicated to transforming healthcare—advancing disease prevention, early detection, and targeted intervention. With a commitment to excellence, we provide world-class molecular diagnostic services that are both accessible and revolutionary, empowering the global community to embrace the full potential of precision medicine.
07/03/2026
Understanding your cancer risk starts with knowing when to test.
Many cancers develop silently — long before symptoms appear. Genetic testing and appropriate screening can help identify risk earlier, allowing doctors to monitor, prevent, or treat cancer more effectively.
Genetic testing may be recommended if you have a personal or family history of cancer, known genetic mutations in the family, or other factors that may increase your risk.
In today’s era of precision medicine, understanding your genetic profile provides valuable insight for early detection, personalised prevention strategies, and more informed healthcare decisions.
Because when it comes to cancer, knowing your risk is the first step toward protecting your health.
If you’re unsure whether genetic testing is right for you, consider speaking with a healthcare professional to explore your options.
06/03/2026
On 12 February, we engaged with the Respiratory Medicine and Laboratory teams at Hospital Raja Permaisuri Bainun for a CME session on the pivotal role of Next Generation Sequencing (NGS) in personalised Non-Small Cell Lung Cancer (NSCLC) care.
The session explored the fundamentals of NGS testing and how genomic biomarkers increasingly shape diagnostic pathways and treatment strategies. Discussions highlighted how comprehensive and sensitive molecular insights can support clinicians in selecting more targeted and personalised therapies for their patients.
Beyond the technology itself, the session also emphasised the importance of best-practice pre-analytical sample handling and preparation, as these critical steps directly influence the accuracy and reliability of NGS results. Strong coordination between clinicians and laboratory teams remains essential to ensure high-quality testing and meaningful clinical interpretation.
As oncology continues to advance towards precision-driven care, close collaboration between diagnostics and clinical teams is key to translating molecular insights into better-informed treatment decisions for patients.
05/03/2026
We were honoured to be invited by the Clinical Haematology team at Hospital Pakar PUSRAWI Kuala Lumpur to deliver a lecture on the evolving role of Next Generation Sequencing (NGS) in the diagnostic and therapeutic management of acute leukaemia.
The session explored how molecular profiling technologies, particularly PCR and NGS, complement each other in the assessment of blood cancers. Through this discussion, clinicians examined how the depth and breadth of genomic information can support more informed diagnostic and treatment decisions in acute leukaemia.
Our consultant pathologist, Dr. Subramanian Yegappan, shared expert insights on Acute Myeloid Leukaemia (AML) mutation and fusion testing, highlighting their clinical relevance and how molecular findings guide therapeutic strategies. The discussion also emphasised the importance of rapid turnaround time when determining the presence or absence of mutations and fusions, as timely molecular information is often critical for initiating the most appropriate treatment.
Real clinical case studies further illustrated how molecular monitoring plays a vital role in managing AML, reinforcing the importance of integrating genomic data into routine haematology practice.
As precision haemato-oncology advances, timely and accurate molecular insights remain essential in guiding diagnosis, prognostication, treatment, and ongoing disease management.
04/03/2026
Advancing cancer care starts with understanding the full molecular picture.
At our recent CME session, we discussed how comprehensive genomic profiling is reshaping modern oncology practice. Real-world data continue to show that tumors are molecularly complex — often harbouring multiple, co-existing, or uncommon alterations that can influence prognosis, resistance, and treatment strategy.
While PCR remains fast and cost-effective, it is inherently targeted — detecting only predefined mutations. Rare variants, complex alterations, and changes outside hotspot regions may go undetected.
In today’s era of precision oncology, what we don’t test for, we don’t find. Broader genomic testing empowers more informed decisions — and ultimately, more personalized cancer care.
03/03/2026
Precision oncology continues to evolve — and so must the way we test.
In this session, we examined the complementary roles of PCR and NGS technologies in molecular profiling, particularly in lung cancer, where testing strategy directly shapes diagnostic accuracy and targeted treatment decisions. While PCR offers speed and cost efficiency, comprehensive NGS profiling provides broader genomic insight — enabling clinicians to detect actionable alterations that may otherwise remain unseen.
We also introduced our expanded NGS & PCR panels designed to support clinical applications across lung, breast, colon, ovarian, endometrial, prostate, gastric, and all other solid tumours.
Beyond technology, the discussion reinforced the importance of stringent validation processes and robust quality control frameworks to uphold high standards of sensitivity and precision in NGS testing. We also shared updates on our subsidised diagnostic support programmes, alongside the expanding role of both tissue and liquid biopsy applications in delivering comprehensive cancer care.
As oncology becomes increasingly molecular, broader genomic testing empowers more informed decisions — and ultimately, more personalised treatment strategies.
28/02/2026
An engaging afternoon at the Oncology Department of Hospital Pulau Pinang brought together 18 oncology professionals to examine how NGS is reshaping clinical decision-making in cancer care.
𝗧𝗵𝗶𝘀 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗲𝘅𝗽𝗹𝗼𝗿𝗲𝗱:
▪️How comprehensive genomic profiling identifies various actionable genomic alterations and genomic signatures in a single assay
▪️The role of NGS results in guiding targeted therapy selection, immunotherapy considerations, and clinical trial matching
▪️Why early and appropriate integration of NGS optimises treatment strategies, reduces ineffective interventions, and improves patient outcomes
🔬Precision oncology is not defined by complexity — but by clarity. The right genomic insight at the right time changes the treatment trajectory.
Thank you to all participants for advancing evidence-based, personalised cancer care together.
27/02/2026
We recently gathered with the Respiratory Medicine Department and Laboratory Department of Hospital Seberang Jaya for an in-depth session on how Next-Generation Sequencing (NGS) is shaping personalised cancer treatment.
𝗧𝗵𝗶𝘀 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗰𝗼𝘃𝗲𝗿𝗲𝗱:
• Core principles of NGS testing and its clinical applications in precision oncology
• Critical pre-analytical sample requirements to ensure accuracy and reliability
• Best-practice alignment between physicians and laboratory teams to enhance test quality and clinical interpretation
When molecular data is accurate, timely, and clinically contextualised, it empowers better therapeutic decisions.
Thank you to everyone who joined us in advancing the conversation around evidence-based, personalised cancer care.
27/02/2026
We gathered 18 haematology professionals at the Haematology Department of Hospital Pulau Pinang for a CME session centred on the clinical complexities of FLT3-mutated acute myeloid leukaemia (AML).
𝗧𝗵𝗲 𝗷𝗼𝗶𝗻𝘁 𝘀𝗲𝘀𝘀𝗶𝗼𝗻 𝗯𝗲𝘁𝘄𝗲𝗲𝗻 𝗢𝗻𝗰𝗼𝗱𝗲 𝗮𝗻𝗱 𝗔𝘀𝘁𝗲𝗹𝗹𝗮𝘀 𝗮𝗱𝗱𝗿𝗲𝘀𝘀𝗲𝗱:
• The poorer prognosis associated with FLT3-ITD mutations — including higher relapse rates and shortened overall survival
• The critical importance of performing molecular testing at diagnosis
• How early genomic insights can expand and optimise treatment strategies in relapsed or refractory settings
In AML, timing matters. Identifying actionable mutations at the point of diagnosis is not an add-on — it is a strategic necessity.
Thank you to all who joined us in strengthening precision-driven haematology care.
18/02/2026
May this season of reflection bring peace, balance, and well-being to you and your loved ones.
16/02/2026
🪭As the Year of the Horse begins, we wish you good health, steady energy, and days that feel balanced and positive.✨
May the year ahead unfold with peace of mind, renewed vitality, and meaningful moments shared with those who matter most.
14/02/2026
Oncode was honoured to participate in 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗗𝗮𝘆 𝟮𝟬𝟮𝟲 at Hospital Tunku Azizah, Kuala Lumpur on 4 February 2026.
The event also marked the 𝗹𝗮𝘂𝗻𝗰𝗵 𝗼𝗳 𝘁𝗵𝗲 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗣𝗼𝗹𝗶𝗰𝘆 𝗳𝗼𝗿 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲𝘀 𝗶𝗻 𝗠𝗮𝗹𝗮𝘆𝘀𝗶𝗮 — a landmark step forward for the rare disease community, championing early diagnosis, affordable treatment, and integrated support.
Malaysia's public healthcare sector currently 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝘀 𝗼𝘃𝗲𝗿 𝟭𝟮,𝟬𝟬𝟬 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗮𝗰𝗿𝗼𝘀𝘀 𝗻𝗲𝗮𝗿𝗹𝘆 𝟱𝟬𝟬 𝗿𝗮𝗿𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀.
As Helen Keller said, “Alone we can do so little; together we can do so much”. Progress in rare disease care thrives when 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀, 𝗰𝗮𝗿𝗲𝗴𝗶𝘃𝗲𝗿𝘀, 𝗰𝗹𝗶𝗻𝗶𝗰𝗶𝗮𝗻𝘀, 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀, 𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀, 𝗮𝗱𝘃𝗼𝗰𝗮𝗰𝘆 𝗴𝗿𝗼𝘂𝗽𝘀, 𝗮𝗻𝗱 𝗽𝗼𝗹𝗶𝗰𝘆𝗺𝗮𝗸𝗲𝗿𝘀 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗲, turning rarity into 𝗰𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝘀𝘁𝗿𝗲𝗻𝗴𝘁𝗵.
At Oncode, we are committed to 𝗽𝗿𝗼𝘃𝗶𝗱𝗶𝗻𝗴 𝗮𝗰𝗰𝗲𝘀𝘀𝗶𝗯𝗹𝗲 𝗮𝗻𝗱 𝗿𝗲𝗹𝗶𝗮𝗯𝗹𝗲 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 that support early, accurate diagnoses — shortening years of uncertainty and guiding personalised care.
Together, we transform uncertainty into diagnosis, diagnosis into treatment, and treatment into hope.
13/02/2026
𝗨𝗻𝗶𝘁𝗲𝗱 𝗯𝘆 𝗨𝗻𝗶𝗾𝘂𝗲
More Than a Diagnosis. Every Story Matters.
As we look back at moments from past scientific meetings, collaborations, and shared milestones, we are reminded that progress in cancer care is built by people — researchers, clinicians, partners, and patients — each with a story that matters.
World Cancer Day’s 2025–2027 theme, “United by Unique,” reflects what we believe in: every cancer journey is different, and meaningful care begins with recognising individuality.
At Oncode Scientific, we remain committed to advancing precision diagnostics and personalised approaches — because no two patients, and no two cancers, are the same.
Together, we move from awareness to action.
Together, we are United by Unique.
Address
Lot 03-01, 3rd Floor. Hap Seng Business Park, No. 12, Persiaran Perusahaan, Unity Square. Seksyen 23, Shah Alam D. E. Shah Alam 40300
Be the first to know and let us send you an email when Oncode Scientific Sdn Bhd posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
ONCODE Scientific Sdn Bhd was founded in 2015, by a strong knowledge-based management and operational team with the combination of more than 85 years of experience in the areas of medical diagnostics and scientific research. It’s aims to be a niche player specializing in Precision Medicine utilizing the techniques of Next Generation Sequencing (NGS), Sanger sequencing, Real-Time & Standard PCR technologies. The team comprises of scientists, geneticists, physicians, pharmacists, bioinformaticians and business veterans who aim to deliver the best quality and affordable molecular diagnostic solutions to the global community.
Oncode laboratory workflows and pipelines include internal and external validation quality controls for compliance with international standards of Good Laboratory Practice (GLP), ISO 15189, the Association for Molecular Pathology (AMP) and the College of American Pathologist (CAP).
The laboratory participates in external quality assurance and proficiency programs including the UK National External Quality Assurance System (UKNEQAS), The European Molecular Genetics Quality Network (EMQN) and the Royal College of Pathologists of Australasia (RCPA).
Oncode Mission
To provide quality diagnostic solutions to customers through the implementation of state-of-the-art laboratory setup designed to worldwide standards, recruitment of dedicated professionals and comprehensive reporting systems.
Oncode Objective
To be a regional one-stop molecular genetics solution center, delivering powerful diagnostic support and insight to medical professionals
恩可德实验室工作流程和管道包括内部和外验证质量控制，以符合良好实验室规范(Good- Laboratory Practice, GLP)，国际标准化组织（ISO15189），分子病理学协会(Association of Molecular Pathology, AMP)和美国病理学家学会(College of American Pathologist, CAP)的国际标准。
该实验室参与外部质量保证和熟练程序，包括英国国家外部质量保证体系(United Kingdom National External Quality Assurance System, UKNEQAS)，欧洲分子遗传学质量网络(European Molecular Genetics Quality Network)和澳大利亚皇家病理学家学会(Royal College of Pathologists of Australasia, RCPA).
